Penumbra, Inc.

Equities

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:01 2024-04-24 pm EDT			5-day change	1st Jan Change
206.2 ^USD	+0.22%		-1.21%	-18.04%

Apr. 23	Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	CI
Apr. 17	DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	MT

Lynn Rothman, the Executive Vice President and Chief Business Officer of Penumbra, Inc., Notifies Her Departure

April 08, 2022 at 04:22 pm EDT

On April 4, 2022, Lynn Rothman, the Executive Vice President and Chief Business Officer of Penumbra, Inc., notified the company of her departure, effective May 2, 2022, in order to start a non-profit organization focused on education.

Latest news about Penumbra, Inc.

Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	Apr. 23	CI
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	Apr. 17	MT
Penumbra, Inc. : The underdog in healthcare	Apr. 11
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	Mar. 27	MT
Truist Securities Cuts Penumbra's Price Target to $280 From $290, Keeps Buy Rating	Mar. 22	MT
Piper Sandler Adjusts Price Target on Penumbra to $290 From $310, Maintains Overweight Rating	Feb. 26	MT
North American Morning Briefing : Traders Await -2-	Feb. 26	DJ
Deutsche Bank Raises Penumbra Price Target to $288 From $257, Maintains Buy Rating	Feb. 23	MT
Truist Securities Cuts Price Target on Penumbra to $290 From $300, Maintains Buy Rating	Feb. 23	MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell	Feb. 23	MT
JPMorgan Downgrades Penumbra to Neutral From Overweight, Cuts Price Target to $250 From $284	Feb. 23	MT
Penumbra Q4 Non-GAAP EPS, Revenue Increase; Shares Fall After-Hours	Feb. 22	MT
Transcript : Penumbra, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (PEN) PENUMBRA Posts Q4 Revenue $284.7M, vs. Street Est of $286.5M	Feb. 22	MT
Earnings Flash (PEN) PENUMBRA Reports Q4 EPS $0.76, vs. Street Est of $0.70	Feb. 22	MT
Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 22	CI
Penumbra, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
RBC Raises Price Target on Penumbra to $289 From $280, Keeps Outperform Rating	Jan. 12	MT
RBC Capital Adjusts Penumbra's Price Target to $280 From $248, Keeps Outperform Rating	Jan. 11	MT
Transcript : Penumbra, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM	Jan. 08
Truist Securities Raises Price Target on Penumbra to $295 From $265, Maintains Buy Rating	Dec. 22	MT
Truist Adjusts Penumbra's Price Target to $265 From $240, Keeps Buy Rating	Dec. 12	MT
Transcript : Penumbra, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-28-2023 01:30 PM	Nov. 28
Penumbra, Inc. Announces First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash for Treatment of Acute Pulmonary Embolism	Nov. 28	CI
Medical device stocks rise in relief after Wegovy heart benefits data	Nov. 13	RE

Chart Penumbra, Inc.

Duration

Period

More charts

Company Profile

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Penumbra, Inc. : The underdog in healthcare

April 11, 2024 at 09:39 pm EDT

More Strategies

Ratings for Penumbra, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

206.2 USD

Average target price

280.1 USD

Spread / Average Target

+35.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
PENUMBRA, INC.	-18.04%	7.96B
SHOCKWAVE MEDICAL, INC.	+72.58%	12.32B
GETINGE AB	+3.57%	5.84B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+6.65%	5.11B
APT MEDICAL INC.	+20.83%	4.28B
ASAHI INTECC CO., LTD.	-20.06%	4B
INARI MEDICAL, INC.	-41.19%	2.15B
SKAN GROUP AG	+0.25%	2.01B
SHENZHEN YHLO BIOTECH CO., LTD.	+4.02%	1.8B
SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD	-41.64%	1.33B

Medical Equipment